Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700
Alkermes plc announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms…
Read More...
Read More...
